Upadacitinib for Sjögren's syndrome
Treatments studied
Part of Immune system & allergy clinical trials.
This study tests whether upadacitinib, a pill that reduces inflammation, can help people with Sjögren's syndrome. It aims to see if the drug can lower disease activity and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You need a confirmed diagnosis of Sjögren's syndrome.
- Your disease activity score must be 5 or higher on the ESSDAI scale.
- You must be on a stable dose of certain medications (like prednisone or hydroxychloroquine) before starting.
- If you were on stronger immunosuppressants (like methotrexate), you must have stopped them at least 8 weeks before screening.
- You cannot have other autoimmune diseases, active infections, or a history of certain cancers.
- You must not have taken a JAK inhibitor (such as upadacitinib) before.
- If you are a woman who can have children, you must use effective birth control during the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called CM336 for people with active Sjögren's syndrome. It aims to see if the drug is safe and effective in reducing symptoms like joint pain and dryness when other treatments haven't worked well.
This study tests a low-dose medication called blinatumomab, which targets certain immune cells, to see if it can help control symptoms of moderate to severe Sjögren's syndrome, especially dry eyes. It is for people who have not gotten enough relief from standard treatments.
This Phase 2 study tests how to measure changes in primary Sjögren’s syndrome symptoms and body activity. It may help researchers confirm which outcomes best reflect improvement and how different patient types respond to treatment.
This study tests an investigational drug called JH013 for primary Sjögren's syndrome. It aims to reduce dryness and other symptoms like fatigue and joint pain, and may help people with moderate to severe disease activity.
This study tests a new medicine called ICP-488 for people with primary Sjögren's syndrome. It may help reduce symptoms like dry eyes and dry mouth by calming the immune system. The trial lasts about 48 weeks and includes regular check-ups.
This clinical trial tests a new drug called telitacicept for people who have both Sjögren's syndrome and interstitial lung disease. The drug aims to reduce the immune system's attack on your body and may help improve lung symptoms.
Hear when a new Primary Sjögren's Syndrome (pSS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.